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1029-18 Promotion of Collateral Growth (Arteriogeneeie) by 
Granuiocyte-Macrophage Colony-Stimulating Factor 
(GM-CSF) in Patients With Coronary Artery Disease 
,. 
Chnstlan, Tilmann Pohl, Kerstin Wustmann, Damian Hutter, Pierre-Alain Nicolet. 
Stephan Windecker, Franz A. Eberii, Bernhard Meier, Cardicbg~ University Hospital, 
Bern, Switzerland. 
Experimentally, activated macrophages have been documented to induce vascular prolif- 
eration. 
Methods: In 21 patients (pts: 11 men, age 74*9years) with three- vessel coronary artery 
disease eligible for PTCA of 21 Stenotic lesion, the effect of GM-CSF on quantitatively 
assessed collateral flow was tested in a randomized. double-blind, placebo-controlled 
fashion. The study protocol consisted of an invasive baseline and follow-up collateral 
flow index (CFI. no unit) measurement immediately before intracoronary (ic) injection of 
4Opg of GM-CSF (n=lO) or placebo (n=ll). and after a Z-week treatment period with 
subcutaneous GM-CSF (lO@kg) or placebo, respectively. CFI was determined by 
simultaneous measurements of mean aortic (P,,. mmHg), coronary wedge (P,,, 
mmHg) and central venous pressure (CVP, mmHg): 
CFl=(P,-CVP)/(P,-CVP). 
Results: see table. ‘: peO.05 
Conclusions: This first clinical study investigating the potential of GM-CSF to improve 
collateral flow in patients with coronary artery disease documents its efficacy in a short- 
term administration protocol. It remains to be detenined whether promotion of collateral 
growth by GM-CSF sustains during long-term follow-up. and whether alternative routes 
of administration are more effective. 
Results 
LV ejection fraction at baseline (%) 
Leucocytes after treatment (109/I) 
Ic ECG ST segment during PTCA after treatment 
normalized 
GM-CSF 
65+10 
14.5f6.7 
4110 
Placebo P 
56il6 NS 
7.5k3.6 0.01 
O/II 0.01 
CFI before treatment 0.21f0.14 0.3ofo.16 NS 
CFI after treatment 0.32iO.24’ 0.23M.11 NS 
Delta CFI after-before treatment +0.11 -0.07 0.01 
1029-19 Therapeutic Angiogeneeie via Selective Retroinfueion 
of FGF-2 and VEGF into the Femoral Vein in the Chronic 
iechemic Hindiimb 
sLebherr, Georges van Degenfeld, Alexander Karl, Florian Pachmayer, Peter 
Boekstegers, Grosshadem University Hospital, Munich, Germany 
With the aim to enhance therapeutic angiogenesis by increasing tissue binding of angio- 
genie growth-factors, selective retroinfusion of the femoral vein was performed in the 
chronically ischemic rabbit hindlimb. In separate scintigrafic experiments, tissue concen- 
tration of Tc-Bgm-Nano-colloids in the ischemic hindlimb was 4-fold increased following 
retroinfusion compared with antegrade delivery. 
Hindlimb ischemia was induced through excision of the femoral artery in 15 male rabbits 
(day 0). 7 days postoperatively selective retroinfusion into the femoral vein of the 
ischemic hindlimb was performed during complete stop of arterial blood flow over 30 min: 
[bFGF-group] with bFGF protein (5Opg). [FGF2+VEGF-group] with a combination of 
FGFP (5Opg) and VEGF Protein (20 pg) or with saline [controls]. 
Results: 
1. collateral growth between day 7 (= baseline) and day 35 (angiography) was higher in 
both treated groups compared with controls (‘= ~‘0.05) 
2. capillary density (alcaline phosphatase staining) was higher in both treated groups 
3. blood flow (tine frame count validated by doppler flow measurement) increased 
between day 7 (= baseline) and day 35 in both treated groups. 
Conclusion: Selective tetroinfusion of FGF2 and/or VEGF protein into the femoral vein 
induced effective therapeutic angiogenesis (collateral and capillary growth), leading lo 
higher blood flow to the ischemic hindlimb. There was a consistent trend towards a more 
effective angiogenesis following retroinfusion of FGFP+VEGF. 
Collateral growth 
Capillary density 
Blood Row 
control 
12.9i3.6 
0.9+0.2 
9*13 
bFGF 
Retroinfusion 
6l.Ot29.0’ 
1.6rO.l’ 
43t3 
bFGF+VEGF 
Retroinfusion 
63.0 i6.0’ 
1.7+0.1’ 
44+6 
1029-20 High Pressure, Retrograde, Coronary Venous Delivery 
of FGF-2 Protein improves Coronary Blood Flow In a 
Porcine Model of Yyocardiai iechemla 
F~ZXQII, Mehrdad Rezaee, Bonnie L. Hiatt, Fumiaki Ikeno, Lynn Bailey, Takeshi 
Suzuki, Niall Herity, Peter J. Fitzgerald, Andrew J. Carter, Alan C. Yeung, Paul G. Yock, 
Stanford IJniversiN Stanford, California. 
Background: Effective delivery of angiogenic factors to ischemic myocardium remains a 
practical challenge. We compared delivery of FGF-2 protein via high pressure, retro- 
grade injection into the anterior interventricular vein (AIV) with intracoronary (IC) adminis- 
tration in a porcine model of chronic myocardlal ischemia. 
Methods: Copper stents were deployed in the left anterior descending (LAD) coronary 
arteries of 17 pigs, resulting in gradual occlusion of the vessel and chronic myocardial 
ischemia. At 4 weeks, myocardial blood flow at rest and during pacing was measured in 
all pigs using fluorescent microspheres. In 6 pigs, FGF-2 protein (6 mcg/kg) was deliv- 
ered via retrograde injection into the AIV at a pressure of 100 mmHg. Six pigs received a 
similar total amount of FGF-2 by IC delivery into the three major coronary arteries, and 3 
pigs served as controls. Four weeks later, myocardial blood flow was reassessed. Post 
sacrifice, the hearts were divided into 40 segments, and myocardial flow in each segment 
was analyzed for microsphere evidence of ischemia prior to and 4 weeks after treatment. 
lschemia was defined as a greater than 10% decrease in blood flow during pacing. The 
average absolute flow, during pacing, in the LAD region before and after treatment was 
also calculated for each arm. 
Results: There were fewer ischemic segments (a decrease in ischemic burden) after 
treatment in 50% (416) of the AIV pigs, versus 17% (l/6) of the IC pigs, and 0% (O/3) of 
the control pigs. The percentage of ischemic myocardial segments decreased by an 
average of 4% per pig in the AIV arm, compared to an increaseof 23% in the IC arm and 
26% in the control arm (p<O.OOl, AIV compared lo IC or control). Average flow (m!Jmin/ 
gm tissue) in the LAD region during pacing increased significantly from pre-treatment to 
after treatment in the AIV arm by 22% (0.73 to 0.93, p<O.OOQl), did not change signifi- 
cantly in the IC arm (1.1 lo 1 .O, p=O.6), and decreased significantly by 20% in the control 
arm (1.4 to 1.1, p=O.O4 ). 
Conclusion: Delivery of FGF-2 protein via high pressure, retrograde injection into the 
AIV may represent a practical and effective means for improving chronic myocardlal 
ischemia. 
1029-21 Acute and Long-Term Safety of Pressurized Myocardial 
Tranevenoue Delivery: Confirmation by Biochemical, 
Echocardiographic, and Histologic Parameters 
N&l&&&, Bonnie L. Hialt, William F. Fearon, Takeshi Suzuki, David J. McEneaney, 
Gerald Berry, Alan C. Yeung, Andrew J. Carter, Peter J. Fitzgerald, Paul 0. Yock, 
Stanford University. Stanford, California, Craigavon Hospital, Portsdown, United 
Kingdom. 
Background: Advances in cardiovascular gene, stem cell and growth factor therapy 
necessitate effective local delivery methods to the heart. This study evaluated the imme- 
diate and long-ten (26-day) safety of regional myocardial drug delivery by pressurized 
myocardial vansvenous injection. Methodr: In 6 anesthetized swine, a balloon-tipped 
catheter cannulated the anterior interventricular vein (AIV) via the internal jugular vein 
and coronary sinus. During balloon occlusion a pressurized injection of saline (IO ml at 
an internal venous pressure of 100 mmHg) was made into the AIV. Cardiac markers were 
measured and echocardiograms were recorded at baseline, 30 minutes. 4 hours and 26 
days post-injection. Histologic analysis was performed at 4 hours or 26 days (n=4 for 
each). Results: There was no echocardiographic evidence of regional wall motion abnor- 
mality in the acute or chronic phase post-injection and limited cardiac marker release 
(Table). Histologic studies showed limited early disruption but no significant myocardial 
necrosis. Concfuslons: Regional pressurized myocardial transvenous delivery is safe 
and well tolerated in the porcine model. The findings support a potential role for protein, 
cell or gene delivery in patients. 
Baseline 30 minutes 4 hours 
CKMB mass (ng/ Troponin T (ngl CKMB Troponin CKMB Troponin 
ml) ml) mass T mass T 
co.10 <O.Ol co.10 0.01 
co.10 co.01 go.10 0.09 
0.13 co.01 0.13 co.01 
0.16 <O.Ol 0.14 co.01 
co.10 <O.Ol <O.lO 0.12 
<O.lO cO.cll <O.lO co.01 
0.16 co.01 co.10 <0.01 
<O.lO <O.Ol co.10 co.01 
Normal ranges: CKMB mass ~5.0 @ml: Troponin T ~0.01 nglml 
